Degeneration of nervous system due to alcohol
Methodology & AI Transparency ⓘ
Degeneration of nervous system due to alcohol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry G31.2: Degeneration of nervous system due to alcohol is managed within Memory & Cognition.
- 3 Typical cash cost range: Clinicians assessing Degeneration of nervous system due to alcohol focus on neurovascular unit dysfunction [Degeneration of nervous system due to alcohol G31.2] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Degeneration of nervous system due to alcohol monitoring tracks MoCA Cognitive Screening in Degeneration of nervous system due to alcohol (G31.2: Score) toward >= 26 / 30 (G31.2).
Ask our AI Specialists anything about Degeneration of nervous system due to alcohol
What Is Degeneration of nervous system due to alcohol?
Recognized across U.S. clinical coding as G31.2 (Memory & Cognition), Degeneration of nervous system due to alcohol is evaluated via volumetric brain MRI [Degeneration of nervous system due to alcohol G31.2] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
In Degeneration of nervous system due to alcohol (G31.2), physiological disruption stems from neurovascular unit dysfunction [Degeneration of nervous system due to alcohol G31.2], informing Alzheimer, Dementia & Memory Health protocols that track Homocysteine & Vitamin in Degeneration of nervous system due to alcohol (G31.2: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.2)).
Common Symptoms & Clinical Signs
- • Presentation of Degeneration of nervous system due to alcohol (G31.2): word-finding pauses, difficulty in Degeneration of nervous system due to alcohol (G31.2: managing multi-step finances,)
- • Secondary Degeneration of nervous system due to alcohol clinical sign: subtle personality shifts, in Degeneration of nervous system due to alcohol (G31.2: apathy, or evening)
- • Symptom flares in Degeneration of nervous system due to alcohol correlating with MoCA Cognitive Screening in Degeneration of nervous system due to alcohol (G31.2: Score) deviation outside >= 26 / 30 (G31.2)
- • Functional memory & cognition impact requiring volumetric brain MRI [Degeneration of nervous system due to alcohol G31.2] evaluation (G31.2)
Degeneration of nervous system due to alcohol Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Degeneration of nervous system due to alcohol (G31.2: Score) | >= 26 / 30 (G31.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Degeneration of nervous system due to alcohol (G31.2: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Degeneration of nervous system due to alcohol (G31.2: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Degeneration of nervous system due to alcohol
Treatment selection for Degeneration of nervous system due to alcohol depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Degeneration of nervous system due to alcohol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Dulaglutide and neurodegeneration biomarkers: REWIND post hoc: What a 3,741-Participant Study Found Dulaglutide-associated changes in biomarkers or SCI were nonsignificant overall. Alzheimer's & dementia : the journal of the Alzheimer's Association • 2026-04-15 • Phase III Randomized Trial | N = 3,741 | 96/100 | PMID 41988866 ↗ |
| New Insights on Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute: What a 357-Participant Study Found Participants with acute schizophrenia with prespecified impairments demonstrated significant cognitive improvement with xanomeline/trospium compared with placebo. The American journal of psychiatry • 2025-03-01 • Phase III Randomized Trial | N = 357 | 93/100 | PMID 39659157 ↗ |
| New Insights on Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular: What a 1,097-Participant Study Found A greater proportion of ranibizumab-treated eyes with nAMD gained/maintained visual acuity at SRF resolution. Ophthalmology. Retina • 2022-11-15 • Phase III Randomized Trial | N = 1,097 | 90/100 | PMID 35654363 ↗ |
| New Insights on Association between screening duration and treatment outcomes in the clinical: What a 1,152-Participant Study Found Linear regression coefficients for screening duration were not statistically significant for BCVA or CST at week 8 (BCVA: B = - 0.058, P = 0.242; CST: B = - 0.050, P = 0.908) or at week 48 (BCVA: B = - 0.015, P = 0.843; CST: B... Scientific reports • 2026-04-02 • Phase III Randomized Trial | N = 1,152 | 90/100 | PMID 41927600 ↗ |
| New Insights on EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE: What a 1,752-Participant Study Found More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the... Retina (Philadelphia, Pa.) • 2022-03-01 • Phase III Randomized Trial | N = 1,752 | 90/100 | PMID 34923515 ↗ |
Degeneration of nervous system due to alcohol Patient Community & “People Like Me” Threads
Filter Degeneration of nervous system due to alcohol community threads and patient logs by age, biological sex, dosage, and treatment duration.